Discovery of Selective <i>Toxoplasma gondii</i> Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis

Allen T. Hopper, A. Brockman, Andy Wise, Julie Gould, Jennifer Barks, Joshua B. Radke, L. David Sibley, Y. Zou, S. Thomas

Journal of Medicinal Chemistry · 2019 · 57 citations · 41 references

DOIFull text

Open access

Concepts

Abstract

A safer treatment for toxoplasmosis would be achieved by improving the selectivity and potency of dihydrofolate reductase (DHFR) inhibitors, such as pyrimethamine (1), for Toxoplasma gondii DHFR ( TgDHFR) relative to human DHFR ( hDHFR). We previously reported on the identification of meta-biphenyl analog 2, designed by in silico modeling of key differences in the binding pocket between TgDHFR and hDHFR. Compound 2 improves TgDHFR selectivity 6.6-fold and potency 16-fold relative to 1. Here, we report on the optimization and structure-activity relationships of this arylpiperazine series leading to the discovery of 5-(4-(3-(2-methoxypyrimidin-5-yl)phenyl)piperazin-1-yl)pyrimidine-2,4-diamine 3. Compound 3 has a TgDHFR IC

References

41